Iovance Biotherapeutics (NASDAQ:IOVA) just reported results for the first quarter of 2024.
- Iovance Biotherapeutics reported earnings per share of -42 cents. This met the analyst estimate for EPS of -42 cents.
- The company reported revenue of $715,000.
- This was 65.46% worse than the analyst estimate for revenue of $2.07 million.